Exhibit 10.1

 
[a1.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a2.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a3.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a4.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a5.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a6.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a7.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a8.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a9.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a10.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a11.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a12.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a13.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a14.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a15.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a16.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
 

 
[a17.jpg]
 
 
 

--------------------------------------------------------------------------------

 
 
AMENDMENT NO. 1
TO PLACEMENT AGENCY AGREEMENT

This Amendment No. 1 (this “Amendment”) to that certain Placement Agency
Agreement (the “Agreement”), dated as of December 6, 2011, by and among TG
Therapeutics, Inc., a Delaware corporation (“TG Therapeutics”), OPN Capital
Markets (“OPN”) and OPN’s affiliated broker-dealer, National Securities
Corporation, is entered into by and among the aforementioned parties and
Manhattan Pharmaceuticals, Inc., a Delaware corporation having an address at 787
Seventh Avenue, 48th Floor, New York, NY 10019 (“Manhattan” and collectively
with the aforementioned parties, the “Parties”), this 30th day of December
2011.  Manhattan agrees to be bound by the terms and conditions of the
Agreement, as amended herein.  All capitalized terms not herein defined shall
have the meaning ascribed to them in the Agreement and that certain Confidential
Offering Memorandum, dated December 1, 2011, as amended or supplemented from
time to time, including all attachments, schedules and exhibits thereto.

The Parties hereby agree to the following amendments:

 
1.
All references to the “Company” in the Agreement and this Amendment shall mean
Manhattan, and in Sections 3(b), 6(d) and 9 of the Agreement, the term
“Disclosure Materials” shall include without limitation the Company’s filings
with the Securities and Exchange Commission.

 
2.
All investors in the Offering shall receive shares of Manhattan’s Common Stock
rather than shares of Convertible Bridge Preferred Stock of TG Therapeutics,
Inc., except that Opus Point Partners, LLC and the Licensors, and any of their
affiliates, may receive shares of Manhattan’s Preferred Stock.  The term
“Shares” in the Agreement shall hereby be amended to mean shares of Manhattan,
the term “Warrants” shall mean warrants to purchase shares of Manhattan’s Common
Stock at an exercise price of $0.04, and the term “Agents’ Warrants” shall mean
warrants to purchase shares of Manhattan's Common Stock at an exercise price of
$0.04.

Each of the Parties shall execute such further documents and instruments and
take such further actions as may reasonably be requested by any other Party in
order to effect the amendments contemplated herein.

Except as set forth herein, the Agreement shall remain in full force and effect.

[Signature Page Follows]
 
 
 

--------------------------------------------------------------------------------

 
 
IN WITNESS WHEREOF, the Parties have duly executed this Amendment, which may be
executed in one or more counterparts, all of which together constituting one and
the same agreement, as of the date first set forth above.
 
 
TG THERAPEUTICS,
INC.                                                                           
 
By: 
/s/ Michael Weiss

 
Name:
Michael Weiss

 
Title:
Chief Executive Officer

 
 
MANHATTAN PHARMACEUTICALS, INC.
 
By: 
/s/ Michael Weiss

 
Name: 
Michael Weiss

 
Title: 
Chief Executive Officer

 
 
NATIONAL SECURITIES CORPORATION
 
By: 
/s/ Jonathan C. Rich

 
Name: 
Jonathan C. Rich

 
Title: 
EVP – Head of Investment Banking

 
 
OPN CAPITAL MARKETS

By: 
/s/ Hany S. Awadalla

 
Name: 
Hany S. Awadalla

 
Title: 
Managing Director